Outlook Therapeutics says FDA approves LYTENAVA for wet AMD

Reuters2026/07/24 18:48

By:Reuters

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Outlook Therapeutics won FDA clearance for LYTENAVA (bevacizumab-vikg) to treat wet age-related macular degeneration.
The decision makes LYTENAVA the first FDA-approved ophthalmic formulation of bevacizumab for wet AMD in the US.
The company expects about 12 years of US market exclusivity under the BPCIA.
Launch preparations are underway, with US availability targeted before year-end.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Outlook Therapeutics Inc. published the original content used to generate this news brief on July 24, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Outlook Therapeutics says FDA approves LYTENAVA for wet AMD

You may also like

Crypto prices